Methotrexate Tapering After Sustained Remission

Duration Before Tapering

The American Academy of Pediatrics recommends continuing methotrexate at full therapeutic dose for a minimum of 12 months after achieving remission before considering any dose reduction 1
The European League Against Rheumatism suggests that for rheumatoid arthritis specifically, patients in persistent remission may consider tapering only after glucocorticoids have been successfully withdrawn 2
Maintaining methotrexate for at least 12 months after meeting inactive disease criteria is recommended for juvenile idiopathic arthritis, with stopping at 6 months versus 12 months showing no substantial difference in relapse rates 1

A conservative approach of reducing the methotrexate dose by 1 mg every 4 weeks (or 2.5 mg every 10 weeks) is recommended once lower doses are reached for rheumatoid arthritis 3
Instead of dose reduction, the dosing interval can be extended to every 2 weeks while maintaining the same dose, showing similar relapse rates compared to dose reduction 4, 5

The European League Against Rheumatism recommends scheduling follow-up visits every 4-8 weeks during the first year of tapering, and extending to every 8-12 weeks in the second year if remission is maintained 3

For inflammatory bowel disease (Crohn's disease), attempt to reduce methotrexate administration after sustained complete remission with normal inflammatory markers for a few months, although the specific tapering schedule is less well-defined in this population 6
For rheumatoid arthritis, tapering should only be considered in cases of sustained long-term remission, and represents a cautious titration as a shared decision between patient and physician 2
When methotrexate is combined with biologic therapy, consider tapering the biologic first before addressing methotrexate 2

Abrupt discontinuation carries a 30-50% relapse rate within 12 months, according to the American College of Rheumatology 1

If disease recurs during tapering, restart methotrexate at the previously effective dose, and for rheumatoid arthritis, the dose should be decreased gradually (within 4-8 weeks) back to the pre-relapse dose after regaining control 3

The European League Against Rheumatism suggests considering maintaining low-dose therapy rather than complete discontinuation in patients with poor prognostic features at baseline 2

The American Academy of Dermatology recommends a slow taper over 2-3 months after sustained clearance or remission of the underlying condition, rather than abrupt discontinuation, to minimize the risk of disease flare 7
For conditions like juvenile idiopathic arthritis, methotrexate should be maintained at the therapeutic dose for at least 12 months before considering tapering, according to The Lancet Child and Adolescent Health 8

The American Academy of Dermatology suggests reducing the weekly methotrexate dose by half and continuing at weekly intervals, then further reducing by 2.5 mg increments every 4-8 weeks if disease remains controlled 9

For patients with psoriasis, consider maintaining a low dose (5-7.5 mg weekly) rather than complete discontinuation in patients with severe or recalcitrant disease, as recommended by the American Academy of Dermatology 9
For rheumatoid arthritis and juvenile idiopathic arthritis, continue methotrexate for at least 12 months after achieving remission, according to The Lancet Child and Adolescent Health 8

Schedule follow-up visits every 4-8 weeks during the tapering process and monitor for signs of disease recurrence at each visit, as suggested by the American Academy of Dermatology 9
Laboratory monitoring (complete blood count, liver function) can be continued at regular intervals but may be extended to every 3 months if stable, according to Praxis Medical Insights 10